title: [Role of slow-acting anti-arthritic agents in osteoarthritis (chondroitin sulfate, glucosamine, hyaluronic acid)].
abstract: Osteoarthritis (OA) is one of the major causes of pain and of outpatient's clinics. 15 years ago, physiopathology of OA and its potential therapeutic targets were announced to be better understood, but the results of therapeutic trials were finally not as convincing as expected. Slow Acting Drugs (SADs) are part of the treatments evaluated in OA. Even if evidence based medicine is low, positive effects of SADs have been observed. We can reasonably propose these treatments for a short test period. It can sometimes enable us to decrease the dosage of others treatment such as NSAIDs. In any case, the physician must properly inform the patient about products available in Switzerland and must be aware of degrees of purity and costs of the products available on the intemet.
authors.affiliation: Service de rhumatologie, médecine physique et réhabilitation, Centre des maladies osseuses, Département de l'appareil locomoteur, Hôpital orthopédique, CHUV, 1011 Lausanne. berengere.aubry@chuv.ch
authors.forename: B
authors.initials: B
authors.lastname: Aubry-Rozier
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005944:Glucosamine / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000150:complications / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D055675:Viscosupplements / Q000627:therapeutic use
chemical_list: D018501:Antirheumatic Agents; D003692:Delayed-Action Preparations; D055675:Viscosupplements; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates; D005944:Glucosamine